OP Asset Management Ltd Buys New Shares in Relay Therapeutics, Inc. $RLAY

Posted by Geri Gentry on Jul 1st, 2026

OP Asset Management Ltd bought a new position in Relay Therapeutics, Inc. (NASDAQ:RLAY – Free Report) in the first quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 29,217 shares of the company’s stock, valued at approximately $291,000.

Several other large investors have also added to or reduced their stakes in the company. Commodore Capital LP purchased a new position in shares of Relay Therapeutics in the second quarter worth about $46,191,000. Spruce Street Capital LP purchased a new stake in Relay Therapeutics in the fourth quarter valued at approximately $25,246,000. Perceptive Advisors LLC purchased a new stake in Relay Therapeutics in the fourth quarter valued at approximately $16,101,000. TCG Crossover Management LLC acquired a new position in Relay Therapeutics in the 3rd quarter worth approximately $9,450,000. Finally, Casdin Capital LLC increased its holdings in Relay Therapeutics by 14.7% in the 4th quarter. Casdin Capital LLC now owns 13,003,574 shares of the company’s stock worth $110,010,000 after buying an additional 1,662,193 shares during the period. Hedge funds and other institutional investors own 96.98% of the company’s stock.

Relay Therapeutics Stock Down 5.2%

RLAY opened at $18.71 on Wednesday. The firm’s fifty day simple moving average is $14.63 and its two-hundred day simple moving average is $11.35. Relay Therapeutics, Inc. has a 52-week low of $3.03 and a 52-week high of $19.93. The company has a market cap of $3.58 billion, a price-to-earnings ratio of -11.92 and a beta of 1.75.

Relay Therapeutics (NASDAQ:RLAY – Get Free Report) last released its earnings results on Tuesday, May 5th. The company reported ($0.41) EPS for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.06). The firm had revenue of $3.00 million for the quarter, compared to analyst estimates of $5.58 million. On average, research analysts forecast that Relay Therapeutics, Inc. will post -1.55 EPS for the current year.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on RLAY shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Relay Therapeutics in a report on Wednesday, April 8th. Barclays raised their target price on shares of Relay Therapeutics from $21.00 to $27.00 and gave the stock an “overweight” rating in a report on Wednesday, May 20th. HC Wainwright upped their price target on shares of Relay Therapeutics from $25.00 to $28.00 and gave the company a “buy” rating in a report on Tuesday, May 26th. Wells Fargo & Company increased their price target on Relay Therapeutics from $17.00 to $21.00 and gave the stock an “overweight” rating in a research report on Tuesday, April 28th. Finally, Citizens Jmp lifted their price objective on Relay Therapeutics from $19.00 to $21.00 and gave the company a “market outperform” rating in a research note on Wednesday, May 20th. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $23.30.

Check Out Our Latest Research Report on Relay Therapeutics

Insider Buying and Selling

In other Relay Therapeutics news, CFO Thomas Catinazzo sold 187,163 shares of the stock in a transaction that occurred on Monday, June 22nd. The stock was sold at an average price of $16.97, for a total transaction of $3,176,156.11. Following the completion of the transaction, the chief financial officer owned 177,461 shares of the company’s stock, valued at $3,011,513.17. This represents a 51.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Donald A. Bergstrom sold 93,456 shares of the firm’s stock in a transaction that occurred on Monday, June 22nd. The shares were sold at an average price of $16.94, for a total value of $1,583,144.64. Following the completion of the transaction, the insider owned 418,557 shares in the company, valued at approximately $7,090,355.58. This trade represents a 18.25% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 321,068 shares of company stock valued at $5,292,189 in the last three months. Insiders own 5.04% of the company’s stock.

Relay Therapeutics Profile

(Free Report)

Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.

The company’s core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.